Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

Milhollen MA, Thomas MP, Narayanan U, Traore T, Riceberg J, Amidon BS, Bence NF, Bolen JB, Brownell J, Dick LR, Loke HK, McDonald AA, Ma J, Manfredi MG, Sells TB, Sintchak MD, Yang X, Xu Q, Koenig EM, Gavin JM, Smith PG.

Cancer Cell. 2012 Mar 20;21(3):388-401. doi: 10.1016/j.ccr.2012.02.009.

2.

Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.

Xu GW, Toth JI, da Silva SR, Paiva SL, Lukkarila JL, Hurren R, Maclean N, Sukhai MA, Bhattacharjee RN, Goard CA, Medeiros B, Gunning PT, Dhe-Paganon S, Petroski MD, Schimmer AD.

PLoS One. 2014 Apr 1;9(4):e93530. doi: 10.1371/journal.pone.0093530. eCollection 2014. Erratum in: PLoS One. 2014;9(10):e112004. Medeiros, Bruno [added].

3.

Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.

Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, Ma J, Loke HK, Lingaraj T, Wu D, Hamman KB, Spelman JJ, Cullis CA, Langston SP, Vyskocil S, Sells TB, Mallender WD, Visiers I, Li P, Claiborne CF, Rolfe M, Bolen JB, Dick LR.

Mol Cell. 2010 Jan 15;37(1):102-11. doi: 10.1016/j.molcel.2009.12.024.

4.

Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.

Yan ZH, Burkhardt A, Loke HK, Chen J, Xu Q, Brauer P, Ma J, Lin Y, Garcia K, Dick LR, Bembenek ME.

Anal Biochem. 2013 Aug 15;439(2):109-15. doi: 10.1016/j.ab.2013.04.016. Epub 2013 Apr 25.

PMID:
23624319
5.

A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924.

Toth JI, Yang L, Dahl R, Petroski MD.

Cell Rep. 2012 Apr 19;1(4):309-16. doi: 10.1016/j.celrep.2012.02.006. Epub 2012 Mar 19.

6.

Absolute quantification of E1, ubiquitin-like proteins and Nedd8-MLN4924 adduct by mass spectrometry.

Yang X, Brownell JE, Xu Q, Zhu F, Ma J, Loke HK, Rollins N, Soucy TA, Minissale JJ, Thomas MP, Mallender WD, Dick LR, Li P, Liao H.

Cell Biochem Biophys. 2013 Sep;67(1):139-47. doi: 10.1007/s12013-013-9625-5.

PMID:
23754621
7.

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy TA, Yu J, Zhang J, Bolen JB, Smith PG.

Blood. 2010 Sep 2;116(9):1515-23. doi: 10.1182/blood-2010-03-272567. Epub 2010 Jun 4.

8.

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, Langston SP.

Nature. 2009 Apr 9;458(7239):732-6. doi: 10.1038/nature07884.

PMID:
19360080
9.

Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

Yao WT, Wu JF, Yu GY, Wang R, Wang K, Li LH, Chen P, Jiang YN, Cheng H, Lee HW, Yu J, Qi H, Yu XJ, Wang P, Chu YW, Yang M, Hua ZC, Ying HQ, Hoffman RM, Jeong LS, Jia LJ.

Cell Death Dis. 2014 Feb 13;5:e1059. doi: 10.1038/cddis.2014.21.

10.

Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ.

Pediatr Blood Cancer. 2012 Aug;59(2):246-53. doi: 10.1002/pbc.23357. Epub 2011 Oct 19. Erratum in: Pediatr Blood Cancer. 2012 Oct;59(4):772.

11.

The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.

Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L, Chu Y, Yi J, Wang X, Sun Y, Jeong LS, Liu J, Jia L.

Cancer Res. 2012 Jul 1;72(13):3360-71. doi: 10.1158/0008-5472.CAN-12-0388. Epub 2012 May 4.

12.

Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.

Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K, Lightcap ES.

Mol Cell Proteomics. 2011 Nov;10(11):M111.009183. doi: 10.1074/mcp.M111.009183. Epub 2011 Aug 26.

13.

Molecular dynamics investigation on the poor sensitivity of A171T mutant NEDD8-activating enzyme (NAE) for MLN4924.

Verma S, Singh A, Mishra A.

J Biomol Struct Dyn. 2014;32(7):1064-73. doi: 10.1080/07391102.2013.804436. Epub 2013 Jun 20.

PMID:
23782099
15.

Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.

Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, Smith PG, Morgan MA, Sun Y.

Cancer Res. 2012 Jan 1;72(1):282-93. doi: 10.1158/0008-5472.CAN-11-2866. Epub 2011 Nov 9.

16.

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS.

Blood. 2010 May 6;115(18):3796-800. doi: 10.1182/blood-2009-11-254862. Epub 2010 Mar 4.

17.

Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.

Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A, Carew JS.

Clin Cancer Res. 2013 Jul 1;19(13):3577-90. doi: 10.1158/1078-0432.CCR-12-3212. Epub 2013 Apr 30.

18.

Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.

Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, Lightcap ES.

Cancer Res. 2013 Jan 1;73(1):225-34. doi: 10.1158/0008-5472.CAN-12-1729. Epub 2012 Oct 24.

19.

Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.

Garcia K, Blank JL, Bouck DC, Liu XJ, Sappal DS, Hather G, Cosmopoulos K, Thomas MP, Kuranda M, Pickard MD, Liu R, Bandi S, Smith PG, Lightcap ES.

Mol Cancer Ther. 2014 Jun;13(6):1625-35. doi: 10.1158/1535-7163.MCT-13-0634. Epub 2014 Mar 26.

20.

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, Yu J, Smith PG, Richardson PG, Anderson KC, Treon SP, Kung AL, Mitsiades CS.

Mol Cancer Ther. 2012 Apr;11(4):942-51. doi: 10.1158/1535-7163.MCT-11-0563. Epub 2012 Jan 12.

Items per page

Supplemental Content

Write to the Help Desk